Clinical trials: Malignant Melanomas
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
The goal of this clinical research study is to learn if GSK2636771 given in combination with pembrolizumab can help to control the disease in patients with refractory (has not responded to treatment) metastatic melanoma.
- Trial name
- NCT03131908
- Testing
- GSK2636771, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's white blood cells combined with melanoma antigens may make the body build an immune response to tumor cells.
- Trial name
- NCT00004025
- Testing
- aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Melanoma
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
The aim of the study is to compare the safety and effectiveness of a new drug called PI-88, when used in combination with an approved chemotherapy drug called dacarbazine, in the treatment of metastatic melanoma.
- Trial name
- NCT00130442
- Testing
- PI-88 and dacarbazine, dacarbazine or DTIC
- Where
- 12 sites in United States, Australia
- Volunteers
- 134 people
- Sponsor
- Cellxpert Biotechnology Corp.
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer
Advanced or Metastatic Melanoma
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations.
- Trial name
- NCT07449754
- Testing
- Belvarafenib, Cobimetinib
- Where
- 10 sites in South Korea
- Volunteers
- 45 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients
The aim of the study is to assess if treatment with IDO/Survivin peptide vaccine can enhance the efficacy of temozolomide chemotherapy in patients with metastatic malignant melanoma.
- Trial name
- NCT01543464
- Testing
- Chemotherapy: Temozolomide
- Where
- Denmark
- Volunteers
- 41 people
- Sponsor
- Inge Marie Svane
Non Small Cell Lung Cancer, Bladder Cancer
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body.
- Conditions
- Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06580938
- Testing
- PF-07921585, Sasanlimab
- Where
- 9 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Uveal Melanoma
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
The goal of this prospective observational study is to learn about patient quality of life and experience and medical information needs during uveal melanoma post-treatment surveillance.
- Trial name
- SALOME Quali (NCT06073548)
- Testing
- Questionnaires and interviews
- Volunteers
- 250 people
- Sponsor
- Institut Curie
Melanoma, Skin
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
The purpose of this study is to determine the signaling pathways and changes in gene expression in melanocytes of subjects with a history of non-melanoma skin cancer who are exposed to oral vitamin D.
- Trial name
- NCT01477463
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Stanford University
Melanoma, Cancer Survivorship
Mentored Community Gardening for Individuals With Skin Cancer
The investigators will conduct a single-arm pilot feasibility trial of mentored community gardening for melanoma survivors integrating dosimeters and accelerometers.
- Conditions
- Melanoma, Cancer Survivorship, Skin Cancer, Basal Cell Carcinoma
- Trial name
- H4H2-AZ (NCT05648604)
- Testing
- Mentored Community Gardening
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Melanoma (Skin)
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease…
- Trial name
- NCT00004152
- Testing
- iodinated contrast dye, computed tomography, positron emission tomography
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients
This trial is a translational proof-of-concept, open-label, prospective cohort study of 60 patients aiming to identify the clinical markers and/or biomarkers associated with therapeutic response to immune checkpoints inhibitors…
- Trial name
- IMMUSPHINX (NCT03627026)
- Testing
- Blood samples will be collected at different time points:
- Where
- 2 sites in France
- Volunteers
- 78 people
- Sponsor
- Institut Claudius Regaud
Metastatic, Melanoma
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
The main purpose of this study is to determine how best to combine hypofractionated radiotherapy, MEDI4736, and tremelimumab and to determine how safe and tolerable hypofractionated radiotherapy, MEDI4736, and tremelimumab are…
- Conditions
- Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer
- Trial name
- NCT02639026
- Testing
- Radiotherapy, MEDI4736, Tremelimumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma
Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma
Melanoma has become a growing interdisciplinary problem in public health worldwide. It characteristically disseminates in an orderly progression through lymphatic channels to the regional lymph node and then to more distant…
- Trial name
- NCT03683550
- Testing
- SLNE with preoperative hybrid SPECT/CT, Standard SLNE
- Where
- 13 sites in Germany
- Volunteers
- 836 people
- Sponsor
- University Hospital, Essen
Metastatic Melanoma
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Purpose of this Pilot Study: The investigators want to study the safety, side effects, and benefits of tumor infiltrating lymphocytes (TILs), when they are given with the drug ipilimumab.
- Trial name
- NCT01701674
- Testing
- Ipilimumab, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Renal Cell Carcinoma, Melanoma
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
- Trial name
- NCT05789069
- Testing
- HFB200603, Tislelizumab
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 83 people
- Sponsor
- HiFiBiO Therapeutics
Melanoma (Skin)
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
Phase II trial to study the effectiveness of O6-benzylguanine and carmustine in treating patients who have unresectable locally recurrent or metastatic melanoma.
- Trial name
- NCT00005961
- Testing
- O6-benzylguanine, carmustine
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Melanoma Molecular Profiling Analysis
There is a significant need to develop new and more effective ways to treat melanoma that will decrease patient morbidity and mortality.
- Trial name
- NCT00889980
- Testing
- Biospecimen banking
- Where
- United States
- Volunteers
- 237 people
- Sponsor
- University of Pittsburgh
Malignant Melanoma
Reducing Symptom Burden Through Physical Exercise in Melanoma Patients
The aim of the clinical trial is to determine whether regular exercise can reduce fatigue in adult patients with stage IIb-IV melanoma undergoing immunotherapy or targeted therapy.
- Trial name
- RESPECT (NCT06985056)
- Testing
- Supervised 12-week Resistance and Endurance Exercise Program
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Universität Duisburg-Essen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.